Tokyo, Sept. 10 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062841) titled 'Relapse Rates, Treatment Patterns, and Adverse Events in Patients with Neuromyelitis Optica Spectrum Disorder: A Study Using a National Database' on Sept. 10.
Study Type:
Observational
Primary Sponsor:
Institute - Chugai Pharmaceutical Co., Ltd.
Condition:
Condition - Neuromyelitis optica spectrum disorder
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To estimate the relapse-free rate and the incidence of serious infections among patients with neuromyelitis optica spectrum disorder.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - Not applica...